Mounjaro sales double this year as obesity drug boom prevails, says maker The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales. Evening Standard · Aug 5
Sales in weight-loss drug Mounjaro double amid surging market appetite Eli Lilly’s chief executive David Ricks told investors that it was ‘building for the future’ The Independent UK · Aug 5
Eli Lilly Could Swing $65.9 Billion After Earnings Earnings are set to hit the tape in a tight window on Wednesday and the options market is already sketching out how much volatility traders are willing to pay for into the prints, according to Benzinga Pro. Benzinga · Aug 4
Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year. International Business Times · Aug 4
A Next-Generation Obesity Drug Has Been Released By Eli Lilly in Early Access to Select Patients Eli Lilly will offer early access to the investigational obesity drug retatrutide after positive Phase 3 trials showed significant weight-loss results. Medical Daily · Aug 4
Michigan Supreme Court Clears the Way for a State Investigation into Eli Lilly Insulin Pricing Michigan's high court ruled 4-3 that the state may investigate Eli Lilly's insulin pricing. The decision authorizes a probe, not a finding of wrongdoing. Medical Daily · Aug 4
What Is Retatrutide? The Next-Gen GLP-1 Poised to Become the Most In-Demand Peptide A deep dive into Retatrutide shows promise—and a lot of danger. Marie Claire · Aug 3
Earnings, PMI and Other Key Things to Watch this Week Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending. Barchart · Aug 2
Daily Oral Weight Loss Pill Outperformed Oral Semaglutide On Weight And Blood Sugar In Type 2 Diabetes In a 1,698-person trial, orforglipron beat oral semaglutide on A1C and weight in type 2 diabetes. Here is what was measured and what was not. Medical Daily · Jul 28
Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated… The Economic Times · Jul 24
Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors. International Business Times · Jul 23
The New Drug Melting Body Fat From 38% To 22% — And The Side Effect Patients Are Ignoring A new weight loss drug is drawing serious attention from the medical community, and the comparisons to Ozempic are coming quickly. But researchers are pointing to one difference between the two that is proving difficult to overlook, and it may change how the conversation around weight loss medication develops from… Bored Panda · Jul 23
The First Oral GLP-1 Weight Loss Pill With No Food or Injection Requirements Is Now Available Eli Lilly's Foundayo (orforglipron) is the first oral GLP-1 obesity pill with no food or water restrictions. FDA approved it April 1, 2026. Here is what patients should know. Medical Daily · Jul 23
Insider Moves Are Sending Mixed Signals Across the Tech Sector Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares. MarketBeat · Jul 22
The Independent UK · Jul 21 Two weight-loss drugmakers in legal battle over which is most effective in helping users shed pounds Novo Nordisk claims Eli Lilly compared peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50-pound weight loss versus 33 pounds
International Business Times · Jul 21 Novo Nordisk Says Eli Lilly Used Misleading Weight Loss Drug Advertising. It's Suing The lawsuit, filed Tuesday, alleges that Eli Lilly violated federal and state false advertising laws by promoting "knowingly outdated clinical trial" results that compare both companies' drugs.
The Economic Times · Jul 21 Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drug Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its drugs with higher doses of Lilly's. Lilly's advertisements allegedly omit newer, higher-dose versions of Novo's medicines. Novo seeks to withdraw…
Kiplinger · Jul 16 Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today While Taiwan Semi's post-earnings drop pressured chipmakers, healthcare names outperformed thanks to Merck's FDA win and Eli Lilly's big buy.
International Business Times · Jul 16 Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion.
Barchart · Jul 16 Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.
The Economic Times · Jul 16 Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes AtaiBeckley's lead candidate, BPL-003, a nasal spray. This move follows increased interest in psychedelic therapies and federal funding for research. The companies expect…
The Guardian - UK · Jul 11 ‘A new consumer’: how weight-loss drugs are shaking up clothes shopping As they slim down, UK and US users of GLP-1 jabs and pills are changing their spending habits – and their wardrobes
Barchart · Jul 7 AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.
Medical Daily · Jul 7 A New FDA-Approved Oral Weight Loss Pill Requires No Fasting: What Makes Foundayo Different from Other GLP-1 Drugs FDA approved Foundayo (orforglipron) on April 1, 2026 — the only oral GLP-1 pill for weight loss you can take any time of day without fasting. Average weight loss: 12.4%. Here's the breakdown.
The Guardian - UK · Jul 6 Wegovy weight-loss pill goes on sale on UK high street and online pharmacies Thousands of people begin receiving their first deliveries of once-a-day medication made by Novo Nordisk